{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:09:49Z","timestamp":1770970189554,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012116","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T00:00:00Z","timestamp":1565395200000}}],"reference-count":70,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012116.pub2","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T16:47:15Z","timestamp":1566233235000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acetylsalicylic acid (aspirin) for schizophrenia"],"prefix":"10.1002","volume":"2019","author":[{"given":"Lena","family":"Schmidt","sequence":"first","affiliation":[{"name":"University of Bristol; Bristol Medical School; 39 Whatley Road Bristol UK BS8 2PL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Phelps","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, University of Nottingham; Jubilee Campus, University of Nottingham Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Friedel","sequence":"additional","affiliation":[{"name":"Hochschule Furtwangen University; Furtwangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Shokraneh","sequence":"additional","affiliation":[{"name":"University of Nottingham; Cochrane Schizophrenia Group, Institute of Mental Health, Division of Psychiatry and Applied Psychology, School of Medicine; Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,8,10]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD012116.pub2-BIB0001|cit1","first-page":"e5848","article-title":"Aspirin inclusion in antipsychotic treatment on severity of symptoms in schizophrenia: a randomized clinical trial","volume":"11","author":"Attari","year":"2017","journal-title":"Iranian Journal of Psychiatry and Behavioral Sciences"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0002|cit2","unstructured":"Burger H Acetylsalicylic acid as an adjuvant therapy for schizophrenia www.isrctn.com"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0003|cit3","unstructured":"Burger H Acetylsalicylic acid for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0008|cit4","volume-title":"Anti-inflammatory Drugs and Psychosis [Ontstekingsremmende Geneesmiddelen en Psychose] [Thesis]","author":"Laan","year":"2008"},{"issue":"5","key":"10.1002\/14651858.CD012116.pub2-BIB0004|cit5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjunct aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0005|cit6","unstructured":"Laan W Phelps E Schmidt L [Personal communication] 2018"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6215-7-31","article-title":"Acetylsalicylic acid as an adjunct therapy for schizophrenia","volume":"7","author":"Laan","year":"2006","journal-title":"Trials"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0007|cit8","unstructured":"Laan W Selten JP Kahn RS Huisman AM Heijnen CJ Neeleman J Acetylsalicylic acid as an adjunct therapy for schizophrenia. Rationale and design of a randomized trial Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: an Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0009|cit9","unstructured":"NTR29 Acetylsalicylic acid as an adjunct therapy for schizophrenia www.trialregister.nl\/trial\/5"},{"issue":"2","key":"10.1002\/14651858.CD012116.pub2-BIB0010|cit10","first-page":"81","article-title":"Interaction of chlorpromazine with aspirin in schizophrenia patients","volume":"2","author":"Rasheed","year":"1992","journal-title":"Pakistan Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0016|cit11","first-page":"S5","article-title":"Positive symptoms respond to add-on aspirin in schizophrenia patients with high sera CRP levels: a post-hoc analysis of an RCT","volume":"39","author":"Weiser","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0011|cit12","first-page":"S516","article-title":"Positive symptoms respond to add-on aspirin in schizophrenia patients with high sera CRP levels: a post-hoc analysis of an RCT","volume":"38","author":"Weiser","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"S1","key":"10.1002\/14651858.CD012116.pub2-BIB0012|cit13","first-page":"S351","article-title":"A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder","volume":"38","author":"Weiser","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0013|cit14","first-page":"S318","article-title":"A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder","volume":"39","author":"Weiser","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0014|cit15","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0920-9964(14)70256-7","article-title":"Positive symptoms respond to add-on aspirin in schizophrenia patients with high sera CRP levels: a post-hoc analysis of an RCT","volume":"153","author":"Weiser","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0015|cit16","first-page":"S560","article-title":"Add-on aspirin is not more effective than placebo for positive symptoms in schizophrenia patients with high plasma CRP levels","volume":"41","author":"Weiser","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0017|cit17","first-page":"S560","article-title":"Add-on aspirin is not more effective than placebo for positive symptoms in schizophrenia patients with high plasma CRP levels","volume":"41","author":"Weiser","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0018|cit18","unstructured":"IRCT201108197373N1 Efficacy of aspirin in the treatment of schizophrenia apps.who.int\/trialsearch\/Trial2.aspx?TrialID=IRCT201108197373N1"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0019|cit19","unstructured":"IRCT201109287660N1 Effect of aspirin augmentation on cognitive & clinical symptoms of schizophrenic patients en.irct.ir\/trial\/8128"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0020|cit20","unstructured":"NCT02047539 Randomized controlled trial of aspirin vs placebo in the treatment of pre-psychosis clinicaltrials.gov\/show\/NCT02047539"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0021|cit21","unstructured":"NCT02685748 Aspirin in young psychotic patients www.clinicaltrials.gov\/ct2\/show\/NCT02685748"},{"issue":"7","key":"10.1002\/14651858.CD012116.pub2-BIB0022|cit22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009205","article-title":"Celecoxib for schizophrenia","author":"Akhondzadeh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD012116.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0024|cit24","volume-title":"Schizophrenia and Mental Health","author":"Barbato","year":"1998"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.biopsych.2013.09.023","article-title":"The epidemiologic evidence linking autoimmune diseases and psychosis","volume":"75","author":"Benros","year":"2014","journal-title":"Biological Psychiatry"},{"issue":"74","key":"10.1002\/14651858.CD012116.pub2-BIB0026|cit26","first-page":"1","article-title":"Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness","volume":"11","author":"Berk","year":"2013","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012116.pub2-BIB0028|cit28","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"9683","key":"10.1002\/14651858.CD012116.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"374","author":"Chalmers","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0030|cit30","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0031|cit31","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD012116.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD012116.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD012116.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.biopsych.2013.12.002","article-title":"The cytokine model of schizophrenia: emerging therapeutic strategies","volume":"75","author":"Girgis","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0038|cit38","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0041|cit41","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0042|cit42","unstructured":"Higgins JP Green S Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0043|cit43","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"6","key":"10.1002\/14651858.CD012116.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/schbul\/sbt141","article-title":"Inflammation and schizophrenia","volume":"39","author":"Kirkpatrick","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2014.00011","article-title":"A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation","volume":"5","author":"Kroken","year":"2014","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0046|cit46","volume-title":"Anti-inflammatory Drugs and Pyschosis [PhD thesis]","author":"Laan","year":"2008"},{"issue":"11","key":"10.1002\/14651858.CD012116.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD012116.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012116.pub2-BIB0051|cit51","first-page":"333","article-title":"Efficient screening for brain dysfunction","volume":"15","author":"Mezzich","year":"1980","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012116.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0055|cit55","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0056|cit56","first-page":"240","volume-title":"Martindale: the Extra Pharmacopoeia","author":"Reynolds","year":"1982"},{"issue":"5","key":"10.1002\/14651858.CD012116.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/h0043220","article-title":"A continuous performance test of brain damage","volume":"20","author":"Rosvold","year":"1956","journal-title":"Journal of Consulting Psychiatry"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0058|cit58","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD012116.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","article-title":"A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia","volume":"65","author":"Simpson","year":"2010","journal-title":"Neuron"},{"issue":"3","key":"10.1002\/14651858.CD012116.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.9758\/cpn.2013.11.3.107","article-title":"The neuroimmunology of schizophrenia","volume":"11","author":"Smyth","year":"2013","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD012116.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4088\/JCP.10r06823","article-title":"Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis","volume":"73","author":"Sommer","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012116.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0064|cit64","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD012116.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"Os","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012116.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0895-4356(93)90075-C","article-title":"Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis?","volume":"46","author":"Veldhuyzen Van Zanten","year":"1993","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012116.pub2-BIB0068|cit68","unstructured":"World Health Organization Schizophrenia [Fact Sheet] www.who.int\/en\/news-room\/fact-sheets\/detail\/schizophrenia"},{"issue":"7","key":"10.1002\/14651858.CD012116.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD012116.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012116","article-title":"Acetylsalicylic acid (aspirin) for schizophrenia","author":"Roberts","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012116.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T09:32:41Z","timestamp":1663147961000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012116.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,10]]},"references-count":70,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012116.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,10]]}}}